Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
This project comprises immunological and virological analyses within a prospective clinical
study of Rituximab (Rtx)-treated blood group incompatible living donor (LD) renal transplant
recipients compared to blood group compatible LD recipients without Rtx induction, and of
living donor compared to deceased donor renal transplant recipients treated with tacrolimus
(Tacr)/mycophenolate sodium (MPS). Aim of this project is to assess short- and long-term
effects of immunosuppressive therapy (Rtx induction) and of living donation on immunological
and histological parameters of graft outcome and on viral replication (BK virus (BKV), JC
virus (JCV), cytomegalovirus (CMV), Epstein Barr virus (EBV)) with the potential to improve
long-term graft outcome and to enable risk estimation of virus disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Giessen
Collaborators:
Astellas Pharma US, Inc. German Cancer Research Center Heidelberg University Novartis